Drug Profile
SAR 161271
Alternative Names: SAR161271Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Antihyperglycaemics; Insulins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 30 Jul 2010 Discontinued - Phase-I/II for Type-1 diabetes mellitus in Germany (SC)
- 15 Jun 2010 Sanofi-aventis completes a phase I/II trial in Type-1 diabetes mellitus in Germany
- 19 Jan 2010 Phase-I/II clinical trials in Type-1 diabetes mellitus in Germany (SC)